http://localhost:8080/xmlui/handle/123456789/8866 2026-04-18T17:15:56Z http://localhost:8080/xmlui/handle/123456789/9086 Title: The Nutritional Management of Patients with Continuous Ambulatory Peritoneal Dialysis Authors: Rudiansyah, Mohammad; Kurniaatmaja, Enita Rakhmawati; Supriyadi, Rudi; Bandiara, Ria; Djallalluddin; Hasrianti, Nuvita Abstract: End-stage kidney disease (ESKD) is a severe final phase of chronic kidney disease (CKD). Currently, it is related to high morbidity and mortality rates, making it an important health issue and a catastrophic disease. There is an increase in the death rate, especially when the underlying metabolic disorders are not treated with renal replacement therapy. Continuous ambulatory peritoneal dialysis (CAPD), or continuous dialysis in the peritoneal cavity, is one of the treatment options available in Indonesia as CKD becomes more prevalent each year, in addition to hemodialysis and kidney transplants. Patients with CKD who are on either hemodialysis or CAPD are frequently malnourished. The primary cause of these nutritional and metabolic disorders in uremic patients has decreased appetite, a major disease symptom. It is also observed that the protein levels in the serum and tissues are typically low, although protein and energy intake have been adjusted to meet standard nutritional guidelines. Also, there is reverse epidemiology in CKD patients, where a higher weight gain could result in a lower risk of mortality than non-CKD patients, where a higher weight gain causes an increased risk of death. Assessment and monitoring of nutritional status are necessary to determine mortality and morbidity due to cardiovascular abnormalities and for prevention and management of other complications in CKD patients undergoing CAPD. Lastly, there is currently a scarcity of research on the nutritional status of CAPD patients. Therefore, risk assessment and nutritional management monitoring can help reduce CKD incidence in patients undergoing CAPD. 2024-07-01T00:00:00Z http://localhost:8080/xmlui/handle/123456789/9085 Title: Re-Emerging Trend of Mpox Infection: The Indonesia’s Experience and Review Authors: Erni Juwita Nelwan; Tanadi, Caroline; Pajala, Fegita Beatrix; Stella, Maureen Miracle; Tandarto, Kevin; Supranoto, Yehuda Tri Nugroho Abstract: Background: Since Monkeypox (mpox) had an outbreak on 6th May 2022 in 75 countries, it has been declared by the World Health Organization (WHO) that mpox is a public health of international emergency concern (PHEIC). WHO declared mpox as PHEIC again in August 204. Indonesia was also affected by the mpox outbreak with most of the cases coming from vulnerable populations. This study aimed to give an overview of mpox as well as the recent outbreak situation and management in Indonesia. Methods: In this narrative review (using PubMed, Scopus, and Cochrane databases combined with countries’ national official reports and grey literatures), we discussed an overview of mpox including epidemiology, morphology, transmission, symptoms, treatment, and prevention. The management of mpox in Indonesia was specifically reviewed. Results: Mpox is an infectious disease caused by the mpox virus which has infected 79,231 individuals globally. In Indonesia, the first mpox case was detected in August 2022 with 0 deaths and 88 confirmed cases as of August 2024. The virus is transmitted via respiratory droplets or direct contact with contaminated objects, surfaces, or mucocutaneous lesions of an infected individual which could lead to symptoms such as epidermal papules-pustules and clinical characteristics of classical smallpox. Although antivirals such as tecovirimat, cidofovir, and brincidofovir have been raised as potential treatments for mpox, these agents were only considered in severe cases in Indonesia. Conclusion: Mpox is a contagious disease that could cause major health problems if left uncontrolled, especially in specific vulnerable populations due to its high morbidity and mortality. Therefore, particular measures must be performed, especially in Indonesia. 2024-07-01T00:00:00Z http://localhost:8080/xmlui/handle/123456789/9083 Title: Efficacy of Tenofovir Disoproxil Fumarate in Preventing Vertical Transmission of Hepatitis B in Mothers with Chronic Hepatitis B: An Evidence-Based Case Report Authors: Felim, Ris Raihan; Hasan, Irsan; Nelwan, Erni Juwita Abstract: Background: Hepatitis B virus infection is the most common cause of chronic hepatitis. Vertical transmission is the main transmission route of this virus. Current prevention involves giving newborns immune prophylaxis within 12 hours of birth. However, there is still a failure of immunoprophylaxis, especially in cases of mothers who have a high viral load or are HBeAg positive. Tenofovir disoproxil fumarate (TDF) is the first-line treatment for chronic hepatitis B and is known to reduce perinatal HBV transmission. This study aims to determine the efficacy of TDF in preventing vertical transmission in pregnant women with chronic hepatitis B. Methods: A literature search was performed on the online databases of PubMed/MEDLINE, Embase, Scopus, Cochrane, and ScienceDirect. The inclusion criteria used were pregnant women with chronic hepatitis B and using TDF antiviral as a transmission prevention therapy with the study design used in the form of a meta-analysis, systematic review, randomized or nonrandomized controlled trial. The outcome of interest was the vertical transmission rate of hepatitis B. Results: There are two studies used with a meta-analysis study design and a nonrandomized controlled trial with a good critical review result of Validity, Importance, and Applicability. TDF significantly prevented vertical transmission of hepatitis B compared to placebo. In addition, TDF was not associated with the incidence of maternal and fetal complications. Conclusion: TDF has high effectiveness in preventing vertical transmission of hepatitis B and is safe to give to pregnant women. 2024-07-01T00:00:00Z http://localhost:8080/xmlui/handle/123456789/9082 Title: Successfull Treatment of Plantar Fasciitis with Perineural Dextrose Injection Authors: Darmawan, Guntur; Rahman, Alif Noeriyanto; Hamijoyo, Laniyati 2024-07-01T00:00:00Z